DK1317488T3 - Stedspecifik, antistofformidlet aktivering af proapoptotiske cytokiner: AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) - Google Patents
Stedspecifik, antistofformidlet aktivering af proapoptotiske cytokiner: AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)Info
- Publication number
- DK1317488T3 DK1317488T3 DK01984646.8T DK01984646T DK1317488T3 DK 1317488 T3 DK1317488 T3 DK 1317488T3 DK 01984646 T DK01984646 T DK 01984646T DK 1317488 T3 DK1317488 T3 DK 1317488T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- mediated
- amaize
- zytokine
- site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10045591A DE10045591A1 (de) | 2000-09-15 | 2000-09-15 | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
| PCT/EP2001/010364 WO2002022680A2 (de) | 2000-09-15 | 2001-09-07 | ORTSSPEZIFISCHE, ANTIKÖRPERVERMITTELTE AKTIVIERUNG PROAPOPTOTISCHER ZYTOKINE: AMAIZe (ANTIBODY-MEDIATED APOPTOSIS INDUCING ZYTOKINE) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1317488T3 true DK1317488T3 (da) | 2013-05-06 |
Family
ID=7656259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01984646.8T DK1317488T3 (da) | 2000-09-15 | 2001-09-07 | Stedspecifik, antistofformidlet aktivering af proapoptotiske cytokiner: AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8980265B2 (da) |
| EP (1) | EP1317488B1 (da) |
| JP (1) | JP2004508819A (da) |
| AU (1) | AU2002218163A1 (da) |
| DE (1) | DE10045591A1 (da) |
| DK (1) | DK1317488T3 (da) |
| ES (1) | ES2403041T3 (da) |
| PT (1) | PT1317488E (da) |
| WO (1) | WO2002022680A2 (da) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US20050100548A1 (en) * | 2001-07-24 | 2005-05-12 | Biogen Idec Ma Inc. | BAFF, inhibitors thereof and their use in the modulation of B-cell response |
| US20030095967A1 (en) * | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| DE10045591A1 (de) | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
| PE20021080A1 (es) * | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| US20080267965A1 (en) * | 2002-02-21 | 2008-10-30 | Kalled Susan L | Use of Bcma as an Immunoregulatory Agent |
| DE10247755B4 (de) | 2002-10-14 | 2006-01-19 | Pfizenmaier, Klaus, Prof. Dr. | Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine |
| GB0308988D0 (en) | 2003-04-17 | 2003-05-28 | Univ Singapore | Molecule |
| FR2856070A1 (fr) * | 2003-06-13 | 2004-12-17 | Bionexis | Molecules pour le ciblage et l'assemblage in situ de proteines therapeutiques et leur utilisation |
| JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| EP2332977B1 (en) * | 2004-07-23 | 2015-11-25 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US8014942B2 (en) * | 2005-06-15 | 2011-09-06 | Airbiquity, Inc. | Remote destination programming for vehicle navigation |
| AU2006303440B2 (en) | 2005-10-21 | 2011-09-08 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
| KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| ATE509033T1 (de) | 2006-03-20 | 2011-05-15 | Univ California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| RU2473362C2 (ru) | 2007-02-01 | 2013-01-27 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
| TWI548647B (zh) | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EA025371B1 (ru) | 2007-02-09 | 2016-12-30 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
| EP2009022A1 (en) * | 2007-06-26 | 2008-12-31 | Apogenix GmbH | Trimeric death ligands with enhanced activity (tenascin) |
| US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| EP2740490A1 (en) * | 2007-10-03 | 2014-06-11 | Cornell University | Treatment of proliferative disorders using antibodies to PSMA |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| LT3494986T (lt) | 2008-08-14 | 2020-07-10 | Acceleron Pharma Inc. | Gdf gaudyklės |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| EP3495000A1 (en) | 2009-02-17 | 2019-06-12 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| US8728479B2 (en) * | 2009-03-31 | 2014-05-20 | The Trustees Of The University Of Pennsylvania | Antigen-binding proteins comprising recombinant protein scaffolds |
| US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
| KR20190090049A (ko) | 2009-06-12 | 2019-07-31 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| IN2012DN02766A (da) * | 2009-09-09 | 2015-09-18 | Acceleron Pharma Inc | |
| PT2483310E (pt) * | 2009-09-29 | 2014-10-07 | Roche Glycart Ag | Anticorpos bi-específicos agonistas do receptor de morte |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| MX354143B (es) | 2009-12-02 | 2018-02-14 | Imaginab Inc | Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso. |
| US8734774B2 (en) | 2010-04-02 | 2014-05-27 | University Of Rochester | Protease activated cytokines |
| US20120121576A1 (en) | 2010-11-08 | 2012-05-17 | Jasbir Seehra | Actriia binding agents and uses thereof |
| EP2694550B1 (en) | 2011-04-01 | 2019-11-27 | Universität Stuttgart | Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof |
| CA2890217C (en) | 2012-11-02 | 2021-07-20 | Yifu FANG | Activin-actrii antagonists and uses for treating bone and other disorders |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| CA2907597A1 (en) * | 2013-05-07 | 2014-11-13 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules |
| AU2015274277B2 (en) | 2014-06-13 | 2021-03-18 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| KR20180050321A (ko) | 2015-08-07 | 2018-05-14 | 이미지냅 인코포레이티드 | 분자를 표적화하기 위한 항원 결합 구조체 |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| EP4367145A2 (en) * | 2021-07-09 | 2024-05-15 | Imaginab, Inc. | Novel antibody sequences for diagnostics and therapeutics |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0574395T3 (da) * | 1990-11-09 | 2002-10-07 | Stephen D Gillies | Cytokin-immunkonjugater |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| DK0835305T3 (da) * | 1995-06-29 | 2006-02-13 | Immunex Corp | Cytokin som inducerer apoptose |
| US6046310A (en) * | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
| AU760010B2 (en) * | 1997-11-18 | 2003-05-08 | Genentech Inc. | DNA19355 polypeptide, a tumor necrosis factor homolog |
| BR9908226A (pt) * | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| AU1467000A (en) * | 1998-11-04 | 2000-05-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A novel tumor necrosis factor family member, drl, and related compositions and methods |
| DE10045591A1 (de) | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
| PL206701B1 (pl) * | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
-
2000
- 2000-09-15 DE DE10045591A patent/DE10045591A1/de not_active Withdrawn
-
2001
- 2001-09-07 PT PT1984646T patent/PT1317488E/pt unknown
- 2001-09-07 WO PCT/EP2001/010364 patent/WO2002022680A2/de active Application Filing
- 2001-09-07 DK DK01984646.8T patent/DK1317488T3/da active
- 2001-09-07 ES ES01984646T patent/ES2403041T3/es not_active Expired - Lifetime
- 2001-09-07 JP JP2002526930A patent/JP2004508819A/ja not_active Withdrawn
- 2001-09-07 EP EP01984646A patent/EP1317488B1/de not_active Expired - Lifetime
- 2001-09-07 AU AU2002218163A patent/AU2002218163A1/en not_active Abandoned
-
2003
- 2003-03-14 US US10/389,223 patent/US8980265B2/en not_active Expired - Lifetime
-
2014
- 2014-11-25 US US14/553,669 patent/US9944708B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9944708B2 (en) | 2018-04-17 |
| US20150152186A1 (en) | 2015-06-04 |
| WO2002022680A2 (de) | 2002-03-21 |
| DE10045591A1 (de) | 2002-04-04 |
| EP1317488A2 (de) | 2003-06-11 |
| PT1317488E (pt) | 2013-05-07 |
| AU2002218163A1 (en) | 2002-03-26 |
| EP1317488B1 (de) | 2013-02-27 |
| WO2002022680A3 (de) | 2002-09-12 |
| US8980265B2 (en) | 2015-03-17 |
| ES2403041T3 (es) | 2013-05-13 |
| JP2004508819A (ja) | 2004-03-25 |
| US20040033511A1 (en) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1317488T3 (da) | Stedspecifik, antistofformidlet aktivering af proapoptotiske cytokiner: AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) | |
| DE60236569D1 (de) | Siliziumoxidmembran | |
| DE60233561D1 (de) | Sprachantwortsystem | |
| NO20040925L (no) | Flat belysningsanordning. | |
| ID29325A (id) | Katalis tembaga raney unggun tetap | |
| ITTO20010756A0 (it) | Disposivito di attuazione di tipo termico. | |
| DK1311267T3 (da) | Retroviral immunoterapi | |
| DE60100024D1 (de) | Keilsockellampe | |
| DE50113226D1 (de) | Halogenglühlampe | |
| FR2805405B1 (fr) | Porte-lampe | |
| ATA8482002A (de) | Rohrheizkörper | |
| DK200000284U3 (da) | Lygteholder til cykel. | |
| ES1049594Y (es) | Dispositivo de señalizacion luminosa. | |
| FR2806205B1 (fr) | Support de disques momentane | |
| ES1052300Y (es) | Dispositivo luminoso de señalizacion. | |
| ITSV20000003A0 (it) | Dispositivo di segnalazione luminosa. | |
| FI4579U1 (fi) | Palolasielementin metallinen pidike | |
| FIU20000008U0 (fi) | Palolasielementin metallinen pidike | |
| DK200100223U3 (da) | Holdersystem | |
| CA94238S (fr) | Gabarit support de disque compact | |
| ES1050793Y (es) | Dispositivo de fijacion de luminarias. | |
| ES1047391Y (es) | Aparato de iluminacion polivalente de techo. | |
| ES1047076Y (es) | Base portafusibles. | |
| DK200100059U3 (da) | Vægeholder | |
| SE0003272D0 (sv) | UV-Searchlight Colorlight |